- Investor's Business Daily•10 hours ago
Celgene won't seek approval for expanded use of Revlimid, which is approved in the U.S to treat multiple myeloma patients.
- Reuters•10 hours ago
Celgene Corp said on Monday that its flagship drug Revlimid failed to extend survival as a maintenance therapy for a type of blood cancer after patients had responded to prior treatment. As a result, the U.S. biotechnology company said it would not seek an additional approval for Revlimid for that use, and its shares fell more than 2 percent. Revlimid, a multiple myeloma treatment with annual sales of about $6 billion, was being tested versus a placebo in patients whose diffuse large B-cell lymphoma had responded to initial treatment with Roche's Rituxan and chemotherapy.
After hours: 104.90-3.03 (-2.81%) as of 7:59 PM EDT
|Bid||104.66 x 100|
|Ask||104.90 x 2200|
|52wk Range||92.98 - 136.40|
|Day's Range||106.73 - 108.14|
|Avg Vol (3m)||4,368,698|
As of 4:00 PM EDT. Market closed.